Ligand’s Fourth Quarter Money Outcomes to be Documented February 3rd
Press launch material from Business Wire. The AP information team was not concerned in its development.
SAN DIEGO–(Small business WIRE)–Jan 20, 2021–
Ligand Prescribed drugs Incorporated (NASDAQ: LGND) offered now information of its plans to report fourth quarter 2020 economical benefits on February 3, 2021. Ligand’s CEO John Higgins, President and COO Matt Foehr and Government Vice President and CFO Matt Korenberg will host the meeting get in touch with.
Fourth Quarter 2020 Earnings Meeting Connect with
|
What:
|
Ligand meeting call to discuss financial effects and deliver normal small business updates
|
|
|
|
|
Date:
|
Wednesday, February 3, 2021
|
|
|
|
|
Time:
|
8:30 a.m. Jap time (5:30 a.m. Pacific time)
|
|
|
|
|
Conference Connect with:
|
Dial (833) 540-1167 within the U.S.
|
|
Dial (929) 517-0358 outside the U.S.
|
|
|
Convention ID is 6081598
|
|
|
|
|
|
Webcast:
|
Live meeting connect with webcast and replay accessible at www.ligand.com
|
About Ligand Prescription drugs
Ligand is a earnings-creating biopharmaceutical organization focused on acquiring or acquiring systems that assist pharmaceutical organizations find and develop medications. Ligand’s organization product makes worth for stockholders by offering a diversified portfolio of biotech and pharmaceutical products income streams that are supported by an successful and reduced company expense structure. Ligand’s objective is to supply traders an chance to take part in the guarantee of the biotech marketplace in a worthwhile, diversified and decrease-hazard enterprise than a usual biotech corporation. Ligand’s business model is based mostly on executing what Ligand does greatest: drug discovery, early-stage drug growth, solution reformulation and partnering. Ligand companions with other pharmaceutical organizations to leverage what they do finest (late-stage growth, regulatory administration and commercialization) to eventually create our income. Ligand’s OmniAb ® know-how platform is a patent-protected transgenic animal platform utilised in the discovery of thoroughly human mono- and bispecific therapeutic antibodies. The Captisol ® system technology is a patent-shielded, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of medication. Ligand’s Protein Expression Engineering ® is a sturdy, validated, cost-powerful and scalable method to recombinant protein creation, and is especially well-suited for complicated, huge-scale protein production that can’t be produced by more regular units. Ab Initio ™ technologies and expert services for the layout and planning of custom made antigens empower the thriving discovery of therapeutic antibodies against tricky-to-obtain mobile targets. Ligand has founded numerous alliances, licenses and other business enterprise interactions with the world’s main pharmaceutical firms together with Amgen, Merck, Pfizer, Roche, Sanofi, Janssen, Takeda, Gilead Sciences, GSK and Baxter Global. For much more facts, you should check out www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
Check out source version on businesswire.com:https://www.businesswire.com/information/house/20210120005045/en/
Make contact with: Ligand Pharmaceuticals Included
Patrick O’Brien
(858) 550-7893LHA Trader Relations
Bruce Voss
(310) 691-7100
Keyword: UNITED STATES NORTH America CALIFORNIA
Business Key phrase: BIOTECHNOLOGY PHARMACEUTICAL Wellness
Source: Ligand Prescribed drugs Included
Copyright Business enterprise Wire 2021.
PUB: 01/20/2021 08:30 AM/DISC: 01/20/2021 08:30 AM
http://www.businesswire.com/news/dwelling/20210120005045/en